Zobrazeno 1 - 10
of 22
pro vyhledávání: ''
Autor:
Gary A. Palmer, Caroline G. Epstein, Michael D. Axelson, Michael E. Salazar, Matthew Kase, Martin C. Stumpe, Calvin McCarter, Ashraf T. Hafez, Joyce O'Shaughnessy, Alexandria M. Bobe, Benjamin D. Leibowitz, Ameen A. Salahudeen, Joshua S.K. Bell, Nike Beaubier, Catherine Igartua, Robert Huether, Mark D. Pegram, Louis E. Fernandes, Ruth A. Pe Benito, Sarah Sammons
Publikováno v:
Clinical Breast Cancer. 21:e340-e361
Objective/Background We performed a retrospective analysis of longitudinal real-world data (RWD) from patients with breast cancer to replicate results from clinical studies and demonstrate the feasibility of generating real-world evidence. We also as
Autor:
Susan Abughosh, Meghana V. Trivedi, Kelvin Lu, Rutugandha Paranjpe, Carine Opsomer, Hanna Zaghloul, Grace S. Hwang, Uzoamaka Abajue
Publikováno v:
Clinical Breast Cancer. 20:520-526
Introduction Adherence to oral endocrine therapy (OET) reduces recurrence risk for hormone receptor (HR)-positive breast cancer (BC). Refill data accessed through electronic health records may provide objective assessment of OET adherence. Our goal w
Autor:
Enrique Soto-Perez-de-Celis, Joanne E. Mortimer, Arnold Rotter, Yuan Yuan, Daneng Li, Christina Yeon, Suzette Blanchard, Rachel Morrison, Vani Katheria, Nimit Sudan, Samuel Chung, J Waisman, Arti Hurria, Jennifer Choi, Ty Lee, Abrahm Levi, Thehang H. Luu, G. Somlo, Anne M. Noonan, Peggy Burhenn, Andrea Rubalcava, Anait Arsenyan
Publikováno v:
Clin Breast Cancer
Introduction Phase II clinical trials including geriatric assessment (GA) measures are critical for improving the evidence base for older adults with cancer. We assessed the efficacy and tolerability of nab-paclitaxel in older adults with metastatic
Autor:
Yoshimasa Miyagawa, Ayako Bun, Yukie Fujimoto, Tomoko Higuchi, Hiromi Ozawa, Michiko Imamura, Yuichi Takatsuka, Kazuhiro Araki, Ayako Kira, Yasuo Miyoshi, Arisa Nishimukai
Publikováno v:
Clinical Breast Cancer. 18:400-409
Although eribulin and nab-paclitaxel are chemotherapy agents widely used for locally advanced or metastatic breast cancer (MBC), their predictive factors remain unknown. Because the absolute neutrophil-to-lymphocyte ratio (NLR) is a significant progn
Autor:
Tu Yi, Yao Feng, Cesar A. Santa-Maria, Chen Chuang, Wang Ling-cheng, Zhang Pengcheng, Tan Yuyan, Lan Meng, Xu Yuanbing, Sun Sheng-rong, Feng Hongfang, Li Juanjuan, Liu Zhongchun, Li Xingrui, Yang Qingfeng, Du Bo
Publikováno v:
Clinical Breast Cancer
PURPOSE We aimed to analyze the psychological status in breast cancer (BC) patients in the epicenter of the COVID-19 pandemic. PATIENTS AND METHODS A total of 658 individuals were recruited from multiple breast cancer centers in Hubei Province. Onlin
Autor:
Michail Alevizakos, Michail Pitiakoudis, Constantinos Simopoulos, Alexandra K. Tsaroucha, Apostolos Gaitanidis, Christos Tsalikidis
Publikováno v:
Clinical Breast Cancer. 18:e469-e476
It has been reported that some patients with breast cancer may refuse cancer-directed surgery, but the incidence in the United States is not currently known. The purpose of this study was to identify the incidence, trends, risk factors, and eventual
Publikováno v:
Clinical breast cancer. 20(5)
Background Disparities in breast cancer survival by race/ethnicity and socioeconomic status have been reported. However, it is unclear if these findings are reproducible among subpopulations. This study aimed to assess if socially oriented factors ar
Autor:
Omar Abdel-Rahman
Publikováno v:
Clinical breast cancer. 20(4)
Introduction The objective of this study was to assess family history links between breast cancer and prostate cancer in a prospectively collected cohort from the Prostate, Lung, Colorectal, and Ovary (PLCO) trial. Patients and Methods This is a seco
Autor:
Byung Joo Chae, Ho Yong Park, Yong Hwa Eom, Sae Byul Lee, Soo Jung Lee, Sei Joong Kim, Tae-Kyung Yoo, Hyungsuk Kim, Heung Kyu Park, Jung Sun Lee, Byung Joo Song
Publikováno v:
Clinical breast cancer. 20(3)
Background A prediction model with high sensitivity for the detection of negative axillary involvement can reduce additional axillary surgery in patients with ductal carcinoma in situ (DCIS) upstaged to invasive cancer while saving patients with pure
Publikováno v:
Clinical Breast Cancer. 20:487-494.e1
Background Our objective was to investigate why early studies regarding adoption of the 21-gene recurrence score (RS) assay did not show an initial reduction in the number of patients with breast cancer receiving real-world chemotherapy. Materials an